Aileron Therapeutics General and Administrative Expenses 2011-2026 | ALRN

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Aileron Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
13.9 M	11.4 M	9.68 M	9.6 M	9.33 M	12.3 M	13.5 M	8.77 M	-	5.06 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
13.9 M	5.06 M	10.4 M

Quarterly General and Administrative Expenses Aileron Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.81 M	2.58 M	2.56 M	-	2.35 M	5.3 M	3.74 M	-	1.96 M	1.89 M	2.18 M	-	2.24 M	2.61 M	2.53 M	-	2.51 M	2.16 M	2.67 M	2.27 M	2.34 M	1.91 M	2.81 M	2.64 M	3.44 M	3.08 M	3.14 M	3.02 M	3.18 M	4.34 M	2.92 M	2.73 M	2.6 M	1.79 M	1.65 M	1.36 M	1.63 M	3.46 M	1.45 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.3 M	1.36 M	2.65 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	160 M	$ 215.54	-1.16 %	$ 5 B	Danmark
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	79.8 M	$ 3.88	-1.27 %	$ 415 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Amphastar Pharmaceuticals AMPH	85.9 M	$ 19.23	-	$ 899 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Corbus Pharmaceuticals Holdings CRBP	15.2 M	$ 8.18	-2.97 %	$ 109 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	166 M	-	-	$ 546 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Cara Therapeutics CARA	27.8 M	-	-3.03 %	$ 260 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
CollPlant Biotechnologies Ltd. CLGN	5.94 M	$ 0.71	17.15 %	$ 8.13 M	Israel
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	46.7 M	$ 1.32	-5.71 %	$ 337 M	Britain
CytomX Therapeutics CTMX	29.8 M	$ 4.24	-4.83 %	$ 585 M	USA
Cyclacel Pharmaceuticals CYCC	5.39 M	-	-5.98 %	$ 34.1 M	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
Genmab A/S GMAB	661 M	$ 25.81	0.51 %	$ 16.6 B	Danmark
Aytu BioScience AYTU	17.4 M	$ 2.65	0.76 %	$ 16.6 M	USA
Dynavax Technologies Corporation DVAX	170 M	-	-	$ 2.02 B	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Enochian Biosciences ENOB	17.9 M	-	-	$ 40.5 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Eton Pharmaceuticals ETON	35.8 M	$ 22.97	-3.53 %	$ 618 M	USA
Exelixis EXEL	519 M	$ 41.57	0.39 %	$ 11.3 B	USA
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Fortress Biotech FBIO	87.7 M	$ 2.92	-2.01 %	$ 60.7 M	USA
Arbutus Biopharma Corporation ABUS	15.9 M	$ 4.31	-2.49 %	$ 826 M	Canada
Homology Medicines FIXX	17.7 M	-	0.77 %	$ 53.4 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA